Cargando…
Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients
Introduction: cytokines and their receptor genes are very polymorphic. SNPs in the promotor region of the gene may influence the rate of cytokine secretion and may affect the biological activity of the encoded cytokine. A number of cytokines and cytokine receptors have been directly linked to the de...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168821/ https://www.ncbi.nlm.nih.gov/pubmed/22567049 |
_version_ | 1782211433300230144 |
---|---|
author | Banu, C Moise, A Arion, CV Coriu, D T̆nase, A Constantinescu, I |
author_facet | Banu, C Moise, A Arion, CV Coriu, D T̆nase, A Constantinescu, I |
author_sort | Banu, C |
collection | PubMed |
description | Introduction: cytokines and their receptor genes are very polymorphic. SNPs in the promotor region of the gene may influence the rate of cytokine secretion and may affect the biological activity of the encoded cytokine. A number of cytokines and cytokine receptors have been directly linked to the development of human cancers. The aim of our study was to determine the cytokine gene polymorphism in Romanian multiple myeloma patients. Material and methods: cytokine genotyping was performed in 80 patients and 100 healthy blood donors using molecular biology methods (SSP–Invitrogen, USA). Results: analyzing each polymorphic site, there was an increased frequency of the following genotypes in patients compared to control group: Interleukin–1beta (IL–1β) pos.+3962 TT, IL–12 pos.–1188 CC, gamma–Interferon (γ–IFN) pos.+874 AA, Transforming Growth Factor– beta1 (TGF– β1) codon10 TT, IL–2 pos.–330 TG and pos.+166 TT, Interleukin–4Receptor alpha (IL–4Rα) pos.–33 TC, IL–10 pos.–1082 GG and pos.–592 CC, IL𢀓6 pos.–174 GG. It should be noted that almost one third of multiple myeloma patients had IL–6 pos.–174 GG genotype and 62% IL–10 GCC haplotype. These identified haplotypes are high interleukins producer, and this fact was confirmed by serum IL–6 and IL–10 levels performed by ELISA and enhanced chemiluminiscence methods. Conclusion: these markers could be successfully used, together with other specific clinical and biological parameters, as reliable individualized prognostic factors in multiple myeloma patients. |
format | Online Article Text |
id | pubmed-3168821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31688212012-05-07 Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients Banu, C Moise, A Arion, CV Coriu, D T̆nase, A Constantinescu, I J Med Life Original Article Introduction: cytokines and their receptor genes are very polymorphic. SNPs in the promotor region of the gene may influence the rate of cytokine secretion and may affect the biological activity of the encoded cytokine. A number of cytokines and cytokine receptors have been directly linked to the development of human cancers. The aim of our study was to determine the cytokine gene polymorphism in Romanian multiple myeloma patients. Material and methods: cytokine genotyping was performed in 80 patients and 100 healthy blood donors using molecular biology methods (SSP–Invitrogen, USA). Results: analyzing each polymorphic site, there was an increased frequency of the following genotypes in patients compared to control group: Interleukin–1beta (IL–1β) pos.+3962 TT, IL–12 pos.–1188 CC, gamma–Interferon (γ–IFN) pos.+874 AA, Transforming Growth Factor– beta1 (TGF– β1) codon10 TT, IL–2 pos.–330 TG and pos.+166 TT, Interleukin–4Receptor alpha (IL–4Rα) pos.–33 TC, IL–10 pos.–1082 GG and pos.–592 CC, IL𢀓6 pos.–174 GG. It should be noted that almost one third of multiple myeloma patients had IL–6 pos.–174 GG genotype and 62% IL–10 GCC haplotype. These identified haplotypes are high interleukins producer, and this fact was confirmed by serum IL–6 and IL–10 levels performed by ELISA and enhanced chemiluminiscence methods. Conclusion: these markers could be successfully used, together with other specific clinical and biological parameters, as reliable individualized prognostic factors in multiple myeloma patients. Carol Davila University Press 2011-08-15 2011-08-25 /pmc/articles/PMC3168821/ /pubmed/22567049 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Banu, C Moise, A Arion, CV Coriu, D T̆nase, A Constantinescu, I Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients |
title | Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients |
title_full | Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients |
title_fullStr | Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients |
title_full_unstemmed | Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients |
title_short | Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients |
title_sort | cytokine gene polymorphisms support diagnostic monitoring of romanian multiple myeloma patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168821/ https://www.ncbi.nlm.nih.gov/pubmed/22567049 |
work_keys_str_mv | AT banuc cytokinegenepolymorphismssupportdiagnosticmonitoringofromanianmultiplemyelomapatients AT moisea cytokinegenepolymorphismssupportdiagnosticmonitoringofromanianmultiplemyelomapatients AT arioncv cytokinegenepolymorphismssupportdiagnosticmonitoringofromanianmultiplemyelomapatients AT coriud cytokinegenepolymorphismssupportdiagnosticmonitoringofromanianmultiplemyelomapatients AT tnasea cytokinegenepolymorphismssupportdiagnosticmonitoringofromanianmultiplemyelomapatients AT constantinescui cytokinegenepolymorphismssupportdiagnosticmonitoringofromanianmultiplemyelomapatients |